Photo taken from Biagio Ricciuti/LinkedIn
Jan 18, 2024, 15:55
Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“Now out in the Journal of Clinical Oncology our effort to elucidate mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC. We identified acquired genomic and immunophenotypic changes that may contribute to the development of resistance to ICI +/- chemotherapy in patients with lung cancer.”
Additional information.
Source: Biagio Ricciuti/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 11, 2024, 21:08
Oct 11, 2024, 21:05
Oct 11, 2024, 21:00
Oct 11, 2024, 20:54
Oct 11, 2024, 20:52
Oct 11, 2024, 20:46
Oct 11, 2024, 20:44